Literature DB >> 31628810

Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis.

Helena Florez1, José Hernández-Rodríguez2, Africa Muxi3, Josep Lluis Carrasco4, Sergio Prieto-González2, Maria C Cid2, Gerard Espinosa2, Jose A Gómez-Puerta5, Ana Monegal1, Núria Guañabens1, Pilar Peris1.   

Abstract

OBJECTIVE: To analyse the clinical utility of trabecular bone score (TBS) evaluation for fracture risk assessment in glucocorticoid (GC)-treated patients compared with BMD assessment.
METHODS: One hundred and twenty-seven patients on GC treatment were included [mean age 62 (18) years, 63% women] in this cross-sectional study. The medical history, anthropometric data, lumbar and femoral BMD (DXA) [considering osteoporosis (OP): T-score ⩽-2.5], TBS (considering degraded microarchitecture: <1.230) and dorsolumbar X-ray [to assess vertebral fractures (VF)] were evaluated. BMD and TBS sensitivity, specificity, and positive and negative predictive values (PPV, NPV) were evaluated to determine the diagnostic accuracy of the two methods.
RESULTS: All patients were receiving GC treatment for autoimmune diseases during 47.7 (68.9) months at a mean daily dose of 14.5 mg; 17% had VF, 28% any type of fragility fracture (VF + non-VF), 29% OP and 52% degraded microarchitecture. Degraded microarchitecture was significantly more frequent than densitometric OP in patients with VF (76% vs 38%) and with any fragility fracture (69% vs 36%). For VF, TBS and BMD sensitivity, specificity, PPV, and NPV were 0.76, 0.53, 0.25 and 0.92, and 0.38, 0.72, 0.22 and 0.85, respectively. Specificity increased to 0.89 for VF and 0.9 for any fragility fracture on combining BMD+TBS. TBS had better ability than BMD to discriminate between patients with fracture, especially VF (area under the curve = 0.73).
CONCLUSION: TBS seems to have greater discriminative power than BMD for fracture risk assessment in GC-treated patients, confirming the utility of this method as a complementary tool in the diagnosis of GC-induced OP.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Glucocorticoid-induced osteoporosis; autoimmune diseases; bone microarchitecture; bone mineral density; discriminatory ability; fracture risk; trabecular bone score; vertebral fractures

Year:  2020        PMID: 31628810     DOI: 10.1093/rheumatology/kez464

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

Review 1.  Management of glucocorticoid-induced osteoporosis.

Authors:  Osvaldo D Messina; Luis Fernando Vidal; Maritza Vidal Vidal; Irene E M Bultink; Hennie G Raterman; William Lems
Journal:  Aging Clin Exp Res       Date:  2021-03-22       Impact factor: 3.636

Review 2.  Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.

Authors:  Michaël R Laurent; Stefan Goemaere; Charlotte Verroken; Pierre Bergmann; Jean-Jacques Body; Olivier Bruyère; Etienne Cavalier; Serge Rozenberg; Bruno Lapauw; Evelien Gielen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

3.  Glucocorticoids and Trabecular Bone Score.

Authors:  Florica Sandru; Mara Carsote; Mihai Cristian Dumitrascu; Simona Elena Albu; Ana Valea
Journal:  J Med Life       Date:  2020 Oct-Dec

4.  Estimation of fracture risk by the FRAX tool in patients with systemic lupus erythematosus: a 10-year longitudinal validation study.

Authors:  Chi Chiu Mok; Sau Mei Tse; Kar Li Chan; Ling Yin Ho
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-09       Impact factor: 5.346

Review 5.  Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover.

Authors:  Chu-Han Cheng; Li-Ru Chen; Kuo-Hu Chen
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

Review 6.  Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes.

Authors:  Manuel Gado; Ulrike Baschant; Lorenz C Hofbauer; Holger Henneicke
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-31       Impact factor: 5.555

7.  A bibliometric and visualization analysis of glucocorticoid-induced osteoporosis research from 2012 to 2021.

Authors:  Buchan Jiang; Chengyao Feng; Chenbei Li; Chao Tu; Zhihong Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

8.  Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease.

Authors:  Edgar Wiebe; Dörte Huscher; Désireé Schaumburg; Andriko Palmowski; Sandra Hermann; Thomas Buttgereit; Robert Biesen; Gerd-Rüdiger Burmester; Yannick Palmowski; Maarten Boers; John H Stone; Christian Dejaco; Frank Buttgereit
Journal:  Ann Rheum Dis       Date:  2022-06-09       Impact factor: 27.973

9.  Application of the Trabecular Bone Score in Clinical Practice.

Authors:  Sung Hye Kong; Namki Hong; Jin-Woo Kim; Deog Yoon Kim; Jung Hee Kim
Journal:  J Bone Metab       Date:  2021-05-31

10.  Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses.

Authors:  Helena Florez; Jose Hernández-Rodríguez; Josep Lluis Carrasco; Sergio Prieto-González; Africa Muxi; Xavier Filella; Silvia Ruiz-Gaspà; José A Gómez-Puerta; Maria Cid; Gerard Espinosa; Ana Monegal; Núria Guañabens; Pilar Peris
Journal:  RMD Open       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.